Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04566536 |
Other study ID # |
APHP191091 |
Secondary ID |
2019-A02744-53 |
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
October 7, 2020 |
Est. completion date |
April 22, 2022 |
Study information
Verified date |
April 2023 |
Source |
Assistance Publique - Hôpitaux de Paris |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Anesthesia quality and safety have improved over the past decades, thanks to improved
monitoring devices. No nociception monitoring is currently part of the standard of care.
Usually, hemodynamic parameters are used to evaluate nociception (heart rate, HR, and mean
arterial pressure, MAP), but none of them are specific. However, nociception evaluation is
critical. Indeed, where excess of nociception can lead to arterial hypotension and
respiratory depression, insufficient nociception can lead to acute postoperative pain, which
is followed by persistent chronic pain in 10-50% of patients. Different monitoring devices
have been developed but none of them are still used in current practice. Recently developed,
the nociception level (NoL) index (MEDASENSE BIOMETRICS Ltd®, Ramat Gan, Israel) is an index
of nociception, based on a nonlinear algorithm combination of heart rate, heart rate
variability, photoplethysmograph wave amplitude, skin conductance, skin conductance
fluctuations, and their time derivatives.
Robotic surgeries have started to spread over the world 20 years ago, claiming to be
mini-invasive with less hemorrhage complications, with better success based on the technical
advantages of the robot allowing better access during anatomical challenges procedures.
Robotic surgery has been suggested to decrease pain during surgery and post-operatively,
because of the decreases abdominal wall constraints induced by the robotic arms compared to
the surgeon arms.
This observational prospective non-interventional monocentric study intend to evaluate the
performance of the NoL index to discriminate protocol-defined nociceptive from non
nociceptive stimuli during robotic surgery.
All patients, scheduled for a robotic surgery procedure, will be orally informed about the
study during the anesthesia consultation. During the procedure, the anesthesia procedure will
be the same for all patients, as part of the usual care in our department. The NoL monitor
will be added for the purpose of this study, but the results will be hidden from all
physicians. All settings will be left the physician in charge. At the end of the surgical
procedure, before transfer to the recovery room, data for the monitor will be extracted on a
dedicated universal serial bus (USB) key. Files will be safely stored under RedCap before
analysis.
Description:
Anesthesia quality and safety have improved over the past decades, thanks to improved
monitoring devices. Excess of anesthetics could lead to arterial hypotension which has been
shown to be associated with increased cardiovascular events. On the other hand, insufficient
anesthetics could lead to awareness and memorization during general anesthesia (GA). Whereas
almost all drugs currently used in the operating room (OR), have a validated monitoring tool,
no nociception monitoring is currently part of the standard of care. Usually, hemodynamic
parameters are used to evaluate nociception (heart rate (HR), and mean arterial pressure
(MAP)), but none of them are specific and several factors in the OR influence these
parameters. There is growing interest in the literature for nociception monitoring. Indeed,
where excess of nociception can lead to arterial hypotension and respiratory depression,
insufficient nociception can lead to acute postoperative pain, which is followed by
persistent chronic pain in 10-50% of patients. Opioids per se can also induce nausea and
vomiting, hyperalgesia for remifentanil.
Different monitoring devices, like the surgical pleth index, pupillometry or the "Analgesia
Nociception Index", have been developed, based on several variables and algorithms, but none
of them are still used in current practice. One of the major reason is that although they
might had some effects on clinical parameters or drugs consumption, none of them had any
influence on patient outcome. Recently developed, the nociception level (NoL) index
(MEDASENSE BIOMETRICS LtdĀ®, Ramat Gan, Israel) is an index of nociception, based on a
nonlinear algorithm combination of heart rate, heart rate variability, photoplethysmograph
wave amplitude, skin conductance, skin conductance fluctuations, and their time derivatives.
One of the first study to report the ability of the NoL index to discriminate noxious from
non-noxious stimuli with high sensitivity and specificity was performed in 2016. In that
randomized trial (continuous infusion of remifentanil target 2 versus 4 ng/ml) enrolling 58
patients undergoing a large range of surgery, the NoL index was superior than the hemodynamic
parameters alone to characterize nociception. In a study enrolling 72 patients randomized
within 6 remifentanil concentration targets undergoing several surgical procedures by the
same authors, the NoL index was not affected by remifentanil doses, whereas it had an
dose-dependent hemodynamic effect on HR and MAP.
Robotic surgeries have started to spread over the world 20 years ago, claiming to be
mini-invasive with less hemorrhage complications, with better success based on the technical
advantages of the robot allowing better access during anatomical challenges procedures.
Debates recently arise based on the procedures cost and the little (or lack) of evidence of
mini-invasive procedures in patients with cancers. Robotic surgery has been suggested to
decrease pain during surgery and post-operatively, in gynecologic, thoracic, and general
procedures although results are controversial, because of the decreases abdominal wall
constraints induced by the robotic arms compared to the surgeon arms. To our knowledge, none
of these studies evaluated pain based on a nociception monitoring device.
This observational prospective non-interventional monocentric study intend to evaluate the
performance of the NoL index to discriminate nociceptive from non nociceptive stimuli during
robotic surgery.
All patients, scheduled for a robotic surgery procedure, will be orally informed about the
study during the anesthesia consultation. During the procedure, the anesthesia procedure will
be the same for all patients, as part of the usual care in our department. Patients will be
closely monitored by electrocardiogram, intermittent blood pressure by arm cuff, continuous
pulse oximetry by finger probe, neuromuscular monitoring by train-of-four (TOF)-Cuff,
bispectral index (BIS) monitoring using the BIS forehead 4-sensor. The NoL monitor will be
added for the purpose of this study, but the results will be hidden. The probe will be placed
on the hand contralateral to the blood pressure arm cuff. Anesthesia will be delivered by
target-controlled infusion of remifentanil and propofol by two separate infusion pumps. Once
consciousness will be lost and a TOF calibration done, neuromuscular blockade will be
performed by rocuronium 0.6 mg/kg. All settings will be left the physician appreciation.
Different stimuli (nociceptive and non-nociceptive) are defined according to protocol (such
as intubation, incision, surgical haemostasia, urinary track catheterā¦) and their time of
arrival will be collected in a Case Report Form. At the end of the surgical procedure, before
transfer to the recovery room, data for the monitor will be extracted on a dedicated USB key.
Files will be safely stored under RedCap before analysis.